Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Donor Lymphocyte Infusion (DLI)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Donor Lymphocyte Infusion (DLI). Displaying page 1 of 1.
    EudraCT Number: 2009-014641-88 Sponsor Protocol Number: STP-LYM-01-V01 Start Date*: 2010-01-14
    Sponsor Name:Medizinische Fakultaet der Technischen Universitaet Muenchen
    Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 posit...
    Medical condition: CD20 positive chronic lymphocytic leukemia (CLL) low and high grade non-Hodgkin´s lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002314-31 Sponsor Protocol Number: DLI-TARGET Start Date*: 2018-08-20
    Sponsor Name:Klinikum der Universität München
    Full Title: Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined with Blinatumomab in Patients with Treatment-Resistant Mixed Chimerism or Minimal Re...
    Medical condition: Subjects with treatment-resistant mixed chimerism or MRD of CD19+ B-precursor ALL after allogeneic SCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10063621 Acute lymphoblastic leukaemia recurrent LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003596-34 Sponsor Protocol Number: CHDM201K12201 Start Date*: 2022-05-30
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib/II, open label study of siremadlin monotherapy and in combination with donor lymphocyte infusion as a treatment for patients with acute myeloid leukemia post-allogeneic stem cell transpl...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002435-28 Sponsor Protocol Number: mHagDC Start Date*: 2012-09-21
    Sponsor Name:University Medical Center Utrecht
    Full Title: A phase I/II “minor histocompatibility antigen” (mHag)-based Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of donor Lymphocyte infus...
    Medical condition: Low grade, intermediate and high grade non Hodgkin lymphoma (NHL), M.Hodgkin, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplasia ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003691-40 Sponsor Protocol Number: LUMC2010-01 Start Date*: 2012-09-19
    Sponsor Name:Leiden University Medical Center
    Full Title: Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood a...
    Medical condition: persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005007-34 Sponsor Protocol Number: 2006-0101 Start Date*: 2007-04-10
    Sponsor Name:UMCU
    Full Title: Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantation
    Medical condition: multiple myeloma patients with relapse or progression of their disease after receiving an allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001080-27 Sponsor Protocol Number: CD45RADLIHaplo Start Date*: 2022-11-23
    Sponsor Name:University Hospital Tuebingen
    Full Title: A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic...
    Medical condition: Patients suffering from hematological malignancies and eligible for haploidentical allogeneic stem cell transplantation. Patients will be included prior start of conditioning for SCT. Inclusion cri...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2008-000413-29 Sponsor Protocol Number: RAMP08 Start Date*: 2008-05-05
    Sponsor Name:GITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS
    Full Title: Randomized study with methylprednisolone 1mg/kg/day for treatment of grade I acute GvHD
    Medical condition: patients developing acute GvHD grade I
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10000802 Acute GVH disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007869-23 Sponsor Protocol Number: PTC-MSC Start Date*: 2009-06-26
    Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
    Full Title: Mesenchymal Stromal Cells (MSC) for the treatment of severe (grade II-IV) steroid-resistant Graft Versus Host Disease (GVHD): a phase I trial
    Medical condition: Graft versus Host disease GvHD steroid resistant
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001361-29 Sponsor Protocol Number: CLWP 001 2008 Start Date*: 2009-10-08
    Sponsor Name:EBMT (European group for Blood and Marrow Transplantation)
    Full Title: Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation
    Medical condition: chronic myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004421-24 Sponsor Protocol Number: LUMC2012-02 Start Date*: 2014-04-14
    Sponsor Name:Leiden Universtity Medical Center
    Full Title: Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation (TCD FLAMSA-RIC alloSCT) in elderly acute myeloid leukemia and high risk myelo...
    Medical condition: acute myeloid leukemia and high risk myelodysplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003554-41 Sponsor Protocol Number: UTA2-1DC Start Date*: 2016-03-15
    Sponsor Name:VU University Medical Center
    Full Title: A phase I/II “minor histocompatibility antigen UTA2-1 loaded, PD-L silenced Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of Donor ...
    Medical condition: Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), non Hodgkin lymphoma (nHL)(any grade), Hodgkin’s lymphoma (HL).
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10020309 Hodgkin's disease, unspecified type LLT
    18.1 100000004864 10066703 Non-Hodgkin's lymphoma progression LLT
    18.1 100000004864 10028228 Multiple myeloma LLT
    18.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005535-90 Sponsor Protocol Number: BHS-TC-10 Start Date*: 2013-12-09
    Sponsor Name:CHU Mont-Godinne
    Full Title: Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogenei...
    Medical condition: Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059034 Acute myeloid leukaemia recurrent PT
    18.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003344-74 Sponsor Protocol Number: HOVON116 Start Date*: 2013-11-12
    Sponsor Name:HOVON Foundation
    Full Title: A phase I/II feasibility study of panoninostat alone and the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with...
    Medical condition: (very) poor risk AML or RAEB with IPSS ≥ 1.5
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024329 Leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002715-34 Sponsor Protocol Number: ADN014 Start Date*: 2018-01-30
    Sponsor Name:ADIENNE SA
    Full Title: A Phase I/II, open label, dose escalation study to investigate the pharmacokinetics, pharmacodynamics, safety and clinical activity of begelomab as an initial treatment of acute Graft-versus-Host D...
    Medical condition: Acute graft versus host disease after allogeneic hematopoietic stem cell transplantation or donor lymphocyte infusion
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004808-60 Sponsor Protocol Number: HD-CAR-1/V04 Start Date*: 2018-04-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial
    Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    23.0 100000004864 10029595 Non-Hodgkin's lymphoma NOS refractory LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001061-83 Sponsor Protocol Number: 2215-CL-0304 Start Date*: 2017-07-13
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with...
    Medical condition: FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) (FLT3/ITD) acute myeloid leukemia (AML) in first morphologic complete remission (CR1) that has been treated with allogeneic hem...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) PL (Completed) DK (Completed) FR (Ongoing) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004104-34 Sponsor Protocol Number: SNDX-5613-0700 Start Date*: 2022-04-20
    Sponsor Name:Syndax Pharmaceuticals, Inc
    Full Title: A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nu...
    Medical condition: Relapsed or Refractory Acute Leukemias
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024330 Leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) DE (Temporarily Halted) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002146-72 Sponsor Protocol Number: CC-5013-AML-002 Start Date*: 2017-07-03
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (REVLIMID®) in Pediatric Subjects from 1 to ≤ 18 Years of Age with Relapse...
    Medical condition: Leukemia, Myeloid
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012984 10000886 Acute myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-002419-24 Sponsor Protocol Number: RG_19-116 Start Date*: 2020-09-23
    Sponsor Name:The University of Birmingham
    Full Title: A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosp...
    Medical condition: Acute Myeloid Leukaemia, Acute lymphoblastic leukaemia, Chronic myelomonocytic leukemia, Myelodysplastic syndromes, Non-Hodgkin lymphoma, Hodgkin lymphoma, Multiple myeloma, Chronic lymphocytic leu...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:06:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA